Advertisement

Clinical Drug Investigation

, Volume 13, Issue 1, pp 8–14 | Cite as

Antianginal Efficacy of the Combination of Trimetazidine-Propranolol Compared with Isosorbide Dinitrate-Propranolol in Patients with Stable Angina

  • Andreas P. Michaelides
  • Konstantinos Spiropoulos
  • Konstantinos Dimopoulos
  • Demetrios Athanasiades
  • Pavlos Toutouzas
Clinical Use

Summary

Trimetazidine is a new anti-ischaemic drug that exerts cytoprotective effects without modifying coronary blood flow or systemic haemodynamics. We tested the antianginal efficacy of trimetazidine in combination with propranolol, using a double-blind isosorbide dinitrate-controlled design. Male patients (n = 53) with stable, effort-induced angina not sufficiently controlled with propranolol 40rng 3 times daily received at random either trimetazidine 20mg 3 times daily (n = 27) or isosorbide dinitrate 10mg 3 times daily (n = 26) for 2 months. From day 0 to day 60, in both groups, there was a decrease in the average number of anginal attacks per week (p < 0.01) and in the weekly consumption of nitroglycerin (p < 0.01), the latter being more decreased in the trimetazidine group (p < 0.05). On exercise testing, both exercise duration and time to 1 mm ST depression were improved in the trimetazidine group at day 60 compared with day 0 values (p < 0.001), while no significant changes were observed in the isosorbide dinitrate group. The total workload increased significantly more in the trimetazidine group than in the isosorbide dinitrate group for patients performing the exercise test on a bicycle (n = 31, p < 0.001), but not on a treadmill (n = 22, p = not significant). We concluded that in patients with stable induced angina not sufficiently controlled with propranolol, a better antianginal efficacy was observed with the addition of trimetazidine than with the addition of isosorbide dinitrate, and this confirmed the clinical interest in the new anti-ischaemic drug.

Keywords

Propranolol Drug Invest Isosorbide Exercise Duration Trimetazidine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Boddeke E, Hugtenburg J, Jap W, et al. New anti-ischaemic drugs: cytoprotective action with no primary haemodynamic effects. TIPS 1989; 10: 397–400PubMedGoogle Scholar
  2. 2.
    Detry JM. Clinical features of an anti-anginal drug in angina pectoris. Eur Heart J 1993; 14 Suppl. G: 18–24PubMedGoogle Scholar
  3. 3.
    Kober G, Buck T, Sievert H, et al. Myocardial cytoprotection during percutaneous transluminal coronary angioplasty: effect of trimetazidine. Eur Heart J 1992; 13: 1109–15PubMedGoogle Scholar
  4. 4.
    Fabiani JN, Ponzio O, Emerit I, et al. Cardioprotective effect of trimetazidine during coronary artery graft surgery. J Cardiovasc Surg 1992; 33: 486–91Google Scholar
  5. 5.
    Brottier L, Barat JL, Combe L, et al. Therapeutic value of a cardioprotective agent in patients with severe cardiomyopathy. Eur Heart J 1990; 11: 207–12PubMedGoogle Scholar
  6. 6.
    De Leiris J, Boucher F. Rationale for trimetazidine administration in myocardial ischaemia — reperfusion syndrome. Eur Heart J 1993; 14 Suppl. G: 34–40PubMedGoogle Scholar
  7. 7.
    Sellier P. Effets de la trimétazidine sur les paramètres ergométriques dans 1’angor d’effort. Etude multicentrique contrôlée à double insu contre placebo. Arch Mal Coeur 1986; 79(9): 1331–6PubMedGoogle Scholar
  8. 8.
    Prasad R, Singh HK. The efficacy of trimetazidine in stable effort angina. A double-blind placebo controlled study. Indian Med J 1989; 83(3): 54–8Google Scholar
  9. 9.
    Dalla-Volta S, Maraglino G, Delia-Valentina B, et al. Comparison of trimetazidine with nifedipine in effort angina: a double-blind, cross-over study. Cardiovasc Drug Ther 1990; 4(4): 853–60CrossRefGoogle Scholar
  10. 10.
    Detry JM, Sellier P, Pennaforte S, et al. Trimetazidine: a new concept in the treatment of angina — comparison with propranolol in patients with stable angina. Br J Clin Pharmacol 1994; 37(3): 279–88PubMedCrossRefGoogle Scholar
  11. 11.
    Frischman WH. β-Adrenoreceptor antagonists: new drugs and new indications. New Engl J Med 1981; 305: 500–6CrossRefGoogle Scholar
  12. 12.
    Bernard R, Eliasch H, Gonin A, et al. Nomenclature and criteria 2 for diagnosis of ischemic heart disease. Report of the Joint International Society and Federation of Cardiology/World Health Organization task force for standardization of clinical nomenclature. Circulation 1979; 59: 607–9CrossRefGoogle Scholar
  13. 13.
    Campeau L. Grading of angina pectoris. Circulation 1976; 54: 522PubMedGoogle Scholar
  14. 14.
    Chierchia S, Muisean L, Davies A, et al. Role of the sympathetic nervous system in the pathogenesis of chronic stable angina. Circulation 1990; 82 Suppl. II: II71–II81PubMedGoogle Scholar
  15. 15.
    Svendsen JH, Amtorp A. Mononitrates in combination with beta-blocker therapy in the treament of severe angina pectoris. Drugs 1987; 33 Suppl. 4: 122–4PubMedCrossRefGoogle Scholar
  16. 16.
    Michaelides AP, Vyssoulis GP, Bonoris PE, et al. Beneficial effects of trimetazidine in man with stabla angina under beta-blocker treatments. Curr Ther Res 1989; 46(3): 565–76Google Scholar
  17. 17.
    Delaye J. Le phénomène de l’échappement dans la pratique thérapeutique de l’angine de poitrine. Presse Med 1988; 17: 996–9PubMedGoogle Scholar
  18. 18.
    Weidemann H, Schuon J, Schober B, et al. Hemodynamic measurements and exercise testing to assess the development of tolerance against slow release isosorbide dinitrate. Z Kardiol 1983; 72: 229–32PubMedGoogle Scholar
  19. 19.
    Pornin M, Harpey C, Allai J, et al. Lack of effects of trimetazidine on systemic hemodynamics in patients with coronary artery disease: a placebo controlled study. Clin Trials Meta-Anal 1994; 29: 49–56Google Scholar
  20. 20.
    Boucher F, Hearse D, Opie L. Effects of trimetazidine on ischemic contracture in isolated perfused rat hearts. J Cardiovasc Pharmacol 1994; 24: 45–9PubMedCrossRefGoogle Scholar
  21. 21.
    Belcher P, Drake-Holland AJ, Hynd JW, et al. Trimetazidine reduces myocardial infarct size, relative to area at risk, after temporary coronary artery occlusion in the rabbit. Br J Pharmacol 1992; 107: 265Google Scholar
  22. 22.
    Chierchia SL, Fragasso G, Metabolic management of ischaemic heart disease. Eur Heart J 1993; 14 Suppl. G: 2–5PubMedGoogle Scholar
  23. 23.
    Hugtenburg JG, Jap TSW, Mably JJ, et al. Cardioprotective effect of trimetazidine and nifedipine in guinea-pig hearts subjected to ischemia. Arch Int Pharmacodyn Ther 1989; 300: 186–208PubMedGoogle Scholar
  24. 24.
    Lavanchy N, Martin J, Rossi A. Antiischemic effects of trimetazidine: 31P-NMR spectroscopy in the isolated rat heart. Arch Int Pharmacodyn Ther 1987; 286: 97–110PubMedGoogle Scholar
  25. 25.
    Aussedat J, Ray A, Kay L, et al. Improvement of long-term preservation of isolated arrested rat heart: beneficial effect of the antiischemic agent trimetazidine. J Cardiovasc Pharmacol 1993; 21(6): 128–35PubMedCrossRefGoogle Scholar
  26. 26.
    Williams FM, Tanda K, Williams TJ. Trimetazidine inhibits neutrophil accumulation after myocardial ischemia and reperfusion in rabbits. J Cardiovasc Pharmacol 1993; 22: 828–33PubMedCrossRefGoogle Scholar
  27. 27.
    Maupoil V, Rochette L, Tabard A, et al. Evolution of free radical formation during low-flow ischemia and reperfusion in isolated rat heart. Cardiovasc Drugs Ther 1990; 4: 791–6PubMedCrossRefGoogle Scholar
  28. 28.
    Fantini E, Demaison L, Sentex E, et al. Some biochemical aspects of the protective effect of trimetazidine on rat cardiomyocytes during hypoxia and reoxygenation. J Moll Cell Cardiol 1994; 26: 949–58CrossRefGoogle Scholar
  29. 29.
    Lagadic-Gossmann D, Le Prigent K, Feuvray D. Effects of trimetazidine on pHi regulation in the rat isolated ventricular myocyte. Br J Pharmacol 1996; 117: 831–8PubMedCrossRefGoogle Scholar
  30. 30.
    Gobel FL, Nordstrom LA, Nelson RR, et al. The rate pressure product as an index of myocardial oxygen consumption during exercise in patients with angina pectoris. Circulation 1978; 57: 549–54PubMedCrossRefGoogle Scholar
  31. 31.
    Myers J, Proelicher VF. Optimizing the exercise test for pharmacological investigations. Circulation 1990; 82: 1839–46PubMedCrossRefGoogle Scholar
  32. 32.
    Northride DB, Grant S, Ford I, et al. Novel exercise protocol suitable for use on a treadmill or a bicycle ergometer. Br Heart J 1990; 64: 331–6Google Scholar

Copyright information

© Adis International Limited 1997

Authors and Affiliations

  • Andreas P. Michaelides
    • 1
  • Konstantinos Spiropoulos
    • 1
  • Konstantinos Dimopoulos
    • 2
  • Demetrios Athanasiades
    • 2
  • Pavlos Toutouzas
    • 1
  1. 1.Department of CardiologyUniversity of Athens, Medical School, Hippokration HospitalAthensGreece
  2. 2.Department of CardiologyRed Cross HospitalAthensGreece

Personalised recommendations